Introduction {#sec1}
============

Breast cancer remains the most common malignant tumor and a leading cause of cancer-related mortality in women worldwide \[[@B1]\]. Breast cancer treatment includes locoregional surgery, systemic chemotherapy, precision radiotherapy, endocrine therapy, biological targeting agents, and a combination of the above, mainly depending on clinical, pathological, and molecular features. Biomarkers are served as surrogates of these features for establishing prognostics and predicting outcomes. Finding more effective, sensitive, and specific biomarkers for the prognosis of patients is therefore urgently needed in breast cancer research \[[@B2]\].

The family of tripartite motif (TRIM) proteins (<http://trimbase.tigem.it/>) is one of the subfamilies of the RING type E3 ubiquitin ligases and contains more than 70 members in human chromosomes \[[@B3]\]. Accumulated evidence has suggested that some members of TRIM are involved in various biological processes including cell growth, apoptosis, transcriptional regulation, and carcinogenesis \[[@B4]\]. For example, knockdown of *TRIM66* inhibited malignant behavior and epithelial--mesenchymal transition in non-small-cell lung cancer, suggesting that *TRIM66* was an oncogene that promoted lung cancer progression \[[@B5]\]. *TRIM36* played a tumor suppressive role by reducing cell proliferation and migration as well as promoting apoptosis in prostate cancer \[[@B6]\]. Researchers and clinicians are increasingly regarding TRIM as important factor in cancer development \[[@B7],[@B8]\].

*TRIM13*, a tumor suppressor gene in the 13q14 chromosome region, was frequently lost in various malignancies \[[@B9]\]. It has been reported to play a role in endoplasmic reticulum-associated degradation and to regulate autophagy caused by endoplasmic stress \[[@B14]\]. To date, caspase-8, Akt, L-type channels, and Nur77 have been shown to be substrates for *TRIM13*-mediated ubiquitination \[[@B16]\]. *TRIM13* over-expression caused stabilization of p53 and decrease of Akt kinase activity followed by induction of apoptosis \[[@B17]\]. Taken together, these findings suggest that *TRIM13* may not only function as a tumor suppressor, but also as a potential predictive biomarker for prognosis of cancer.

In the present study, we performed a bioinformatics analysis of the clinical parameters and survival data as it relates to *TRIM13* in breast cancer patients using several large online databases in order to evaluate the prognostic significance of *TRIM13* gene in breast cancer treatment.

Materials and methods {#sec2}
=====================

Oncomine {#sec2-1}
--------

The Oncomine (<http://www.oncomine.org>) is a web-based data mining platform aimed at facilitating new discovery from genome-wide expression analysis \[[@B20]\]. *TRIM13* gene was queried in the database and the results were filtered by selecting breast cancer and Cancer versus Normal Analysis. The threshold included fold change ≥2 in expression between cancers and normal tissues, *P*-value ≤1E-4, and gene rank ≥ top 10%. The comparisons of mRNA levels of *TRIM13* in breast cancer and normal tissues in each individual dataset were analyzed using the Student's *t* test. Gene co-expressed with *TRIM13* was also analyzed.

bcGenExMiner {#sec2-2}
------------

The Breast Cancer Gene-Expression Miner v4.1 (bcGenExMiner v4.1, <http://bcgenex.centregauducheau.fr/BC-GEM>), a mining tool of 36 published annotated genomics data (total of 5861 patients), was used to analyse *TRIM13* gene with clinical parameters such as age, Scarff--Bloom--Richardson (SBR) grade, Nottingham prognostic index (NPI), estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor-2 (HER-2), and nodal status using the expression module \[[@B21],[@B22]\]. Relevance of *TRIM13* and metastatic relapse event was calculated using the prognostic module, and correlation of *TRIM13* and *RAB11FIP2* was assessed using the correlation module. Data were last updated on December 2017.

PrognoScan {#sec2-3}
----------

The PrognoScan (<http://www.prognoscan.org/>) is a popular online database for evaluating the biological relationship between gene expression and survival data including distant metastasis free survival, relapse free survival, and disease specific survival in breast cancer patients across a large collection of publicly available cancer microarray datasets \[[@B23]\]. This tool could automatically calculate *P*-value, HR, and 95% confidence intervals based on a certain gene expression. Data were last updated on March 2013.

UCSC Xena {#sec2-4}
---------

The UCSC Xena (<http://xena.ucsc.edu/>) is a functional genomics browser that provides visualization and integration for analyzing and viewing the public data hubs. The heat map was generated by data mining in The Cancer Genome Atlas (TCGA) Breast Cancer using the UCSC Xena browser.

Results {#sec3}
=======

Reduced expression of *TRIM13* gene in breast cancer patients {#sec3-1}
-------------------------------------------------------------

We first measured the expression of *TRIM13* gene in 20 common types of cancer and compared its level to normal tissues using the Oncomine online database. Increased level of *TRIM13* (red) was found in brain cancer, lung cancer, and lymphoma; whereas, decreased level of *TRIM13* (blue) was observed in esophageal cancer, leukemia, ovarian cancer, and especially breast cancer ([Figure 1](#F1){ref-type="fig"}). Oncomine analysis also revealed that *TRIM13* was significantly lower-expressed in invasive ductal and invasive lobular breast carcinoma, invasive lobular breast carcinoma, invasive ductal breast carcinoma, tubular breast carcinoma, mucinous carcinoma, ductal breast carcinoma *in situ*, breast carcinoma, invasive breast carcinoma, and medullary carcinoma with respect to normal individuals ([Figure 2](#F2){ref-type="fig"}A--I, [Table 1](#T1){ref-type="table"}).

![Expression of *TRIM13* gene in 20 common cancers versus paired normal tissues using the Oncomine database with the threshold of fold change ≥2, *P*-value ≤1E-4, and gene rank ≥ top 10%\
Red and blue respectively stand for the numbers of datasets with statistically significant (*P*\<0.05) increased and decreased levels of *TRIM13* gene.](bsr-39-bsr20190285-g1){#F1}

![Box plot comparing *TRIM13* expression in normal individuals and breast cancer patients obtained from the Oncomine database\
Analysis is shown for invasive ductal and invasive lobular breast carcinoma (**A**), invasive lobular breast carcinoma (**B**), invasive ductal breast carcinoma (**C**), tubular breast carcinoma (**D**), mucinous carcinoma (**E**), ductal breast carcinoma *in situ* (**F**), breast carcinoma (**G**), invasive breast carcinoma (**H**), and medullary carcinoma (**I**).](bsr-39-bsr20190285-g2){#F2}

###### *TRIM13* expression among different subtypes of breast cancer and normal individuals using the Oncomine database

  Breast cancer subtype                                   *P*-value   *t* test   Fold change   Sample
  ------------------------------------------------------- ----------- ---------- ------------- --------
  Invasive ductal and invasive lobular breast carcinoma   2.39E-55    −23.164    −2.710        90
  Invasive lobular breast carcinoma                       1.39E-64    −22.594    −2.554        148
  Invasive ductal breast carcinoma                        1.63E-92    −37.680    −2.773        1556
  Tubular breast carcinoma                                2.41E-41    −21.724    −3.089        67
  Mucinous breast carcinoma                               7.09E-32    −20.140    −2.875        46
  Ductal breast carcinoma *in situ*                       1.10E-7     −11.852    −3.017        10
  Breast carcinoma                                        1.28E-8     −10.636    −2.893        14
  Invasive breast carcinoma                               1.78E-8     −8.060     −2.120        21
  Medullary breast carcinoma                              5.66E-13    −10.639    −2.662        32

*TRIM13* expression and clinical parameters of breast cancer patients {#sec3-2}
---------------------------------------------------------------------

We next evaluated *TRIM13* expression among different groups of patients based on several clinical parameters using the bc-GenExMiner software. For age criteria, no significant difference was found between ≤51 year and \>51 year group ([Figure 3](#F3){ref-type="fig"}A, [Table 2](#T2){ref-type="table"}). The SBR is a histological grade that evaluates tubule formation, nuclear characteristics of pleomorphism, and mitotic index. Based on tumor size, lymph node stage, and tumor grade, the NPI has been validated to stratify patients into additional prognostic groups. The SBR grade and NPI index are two accepted prognostic factors for breast cancer \[[@B24],[@B25]\]; more advanced SBR grade and NPI index were associated with lower *TRIM13* level ([Figure 3](#F3){ref-type="fig"}B,C). ER-positive or PR-positive breast cancer patients tended to express higher *TRIM13* gene compared with ER-negative or PR-negative patients ([Figure 3](#F3){ref-type="fig"}D,E; [Table 2](#T2){ref-type="table"}). Regarding HER-2, there was no significant difference between positive and negative group ([Figure 3](#F3){ref-type="fig"}F, [Table 2](#T2){ref-type="table"}). Patients with nodal-positive status showed reduced expression of *TRIM13* than nodal-negative patients ([Figure 3](#F3){ref-type="fig"}G, [Table 2](#T2){ref-type="table"}). Moreover, *TRIM13* was significantly elevated in non-triple-negative and non-basal-like breast cancer patients with respect to triple-negative and basal-like breast cancer patients ([Figure 3](#F3){ref-type="fig"}H,I; [Table 2](#T2){ref-type="table"}).

![Box plot evaluating *TRIM13* expression among different groups of patients based on clinical parameters using the bc-GenExMiner software\
Analysis is shown for age (**A**), SBR grade (**B**), NPI index (**C**), ER (**D**), PR (**E**), HER-2 (**F**), nodal status (**G**), triple-negative status (**H**), and basal-like status (**I**).](bsr-39-bsr20190285-g3){#F3}

###### Relationship between *TRIM13* expression and clinical parameters of breast cancer patients using the bc-GenExMiner database

  Variables                    No. of patients   *TRIM13* mRNA   *P*-value
  ---------------------------- ----------------- --------------- -----------
  **Age**                                                        0.9509
  ≤51                          1358              \-              
  \>51                         2086              \-              
  **ER**                                                         \<0.0001
  Negative                     1525              \-              
  Positive                     3864              Increased       
  **PR**                                                         0.0006
  Negative                     936               \-              
  Positive                     1390              Increased       
  **HER-2**                                                      0.5603
  Negative                     1357              \-              
  Positive                     198               \-              
  **Nodal status**                                               0.0351
  Negative                     2420              Increased       
  Positive                     1484              \-              
  **Triple-negative status**                                     0.0008
  Non-triple-negative          4040              Increased       
  Triple-negative              374               \-              
  **Basal-like status**                                          \<0.0001
  Non-basal-like               4157              Increased       
  Basal-like                   1128              \-              

*TRIM13* expression and survival data of breast cancer patients {#sec3-3}
---------------------------------------------------------------

We then investigated the prognostic value of *TRIM13* gene using the PrognoScan database. Higher expression of *TRIM13* (red) was significantly related to preferable distant metastasis free survival ([Figure 4](#F4){ref-type="fig"}A, [Table 3](#T3){ref-type="table"}). Breast cancer patients with increased *TRIM13* level (red) presented better relapse free survival ([Figure 4](#F4){ref-type="fig"}B--D, [Table 3](#T3){ref-type="table"}). Conversely, down-regulated *TRIM13* gene (blue) was strongly associated with worse disease specific survival ([Figure 4](#F4){ref-type="fig"}E, [Table 3](#T3){ref-type="table"}). To further investigate the role of *TRIM13* in breast cancer prognosis, we used the bc-GenExMiner software to verify our findings. *TRIM13* was observed to be positively correlated with metastatic relapse free survival, as suggested by the survival curve and forest plot ([Figure 4](#F4){ref-type="fig"}F--G, [Table 3](#T3){ref-type="table"}).

![Survive curve and forest plot evaluating the prognostic value of *TRIM13* using the PrognoScan and bc-GenExMiner database\
Analysis is shown for distant metastasis free survival (**A**), relapse free survival for different probe (**B--D**), disease specific survival (**E**), metastatic relapse free survival (**F**), and forest plot (**G**). For A--E, red and blue stand for high and low expression of *TRIM13* gene, respectively.](bsr-39-bsr20190285-g4){#F4}

###### *TRIM13* expression and survival data of breast cancer patients using the PrognoScan database

  Dataset          Probe ID       End point                          No.   Cox *P*-value   HR
  ---------------- -------------- ---------------------------------- ----- --------------- ---------------------
  GSE9195          203659_s\_at   Distant metastasis free survival   77    0.005338        0.16 \[0.04--0.58\]
  GSE9195          229943_at      Relapse free survival              77    0.049747        0.62 \[0.38--1.00\]
  GSE9195          230192_at      Relapse free survival              77    0.009577        0.26 \[0.09--0.72\]
  GSE9195          203659_s\_at   Relapse free survival              77    0.001462        0.16 \[0.05--0.49\]
  GSE3494--GPL96   203659_s\_at   Disease specific survival          236   0.011486        0.23 \[0.08--0.72\]

Co-expression of *TRIM13* gene {#sec3-4}
------------------------------

We finally checked the co-expression of *TRIM13* gene using the Oncomine database. The co-expression profile of *TRIM13* was identified with a large cluster of 8603 genes across 174 cancer samples including 26 breast carcinomas ([Figure 5](#F5){ref-type="fig"}A). Data mining using the bc-GenExMiner software revealed a positive correlation between *TRIM13* and *RAB11FIP2* expression ([Figure 5](#F5){ref-type="fig"}B). After analyzing breast cancer patient data in the TCGA database using the UCSC Xena web-based tool, we also confirmed a positive correlation between *TRIM13* and *RAB11FIP2* expression, as shown in the heat map ([Figure 5](#F5){ref-type="fig"}C).

![Co-expression of *TRIM13* gene\
(**A**) *TRIM13* co-expression of genes identified using the Oncomine database. (**B**) Correlation between *TRIM13* and *RAB11FIP2* expression in breast cancer analyzed using the bc-GenExMiner software. (**C**) Heat map of *TRIM13* and *RAB11FIP2* expression across a 50-gene qPCR assay (PAM50) breast cancer subtypes in the TCGA database generated using the UCSC Xena web-based tool.](bsr-39-bsr20190285-g5){#F5}

Discussion {#sec4}
==========

*TRIM13*, a member of the TRIM family, has been reported to play a role in diverse cellular functions such as cell growth, immunity, and tumorigenesis including lipoma, leukemia, and myeloma \[[@B9],[@B26],[@B27]\]. *TRIM13* over-expression caused increased stability of p53 and decreased activity of Akt kinase, resulting in induction of apoptosis \[[@B17]\]. However, the significance of *TRIM13* expression in the development and prognosis of breast cancer remains largely unclear. To the best of our knowledge, this is the first study to identify *TRIM13* as a potential predictive biomarker for prognosis of breast cancer.

In the present work, we performed a bioinformatics analysis of the clinical parameters and survival data as it relates to *TRIM13* in breast cancer patients by pooling and analyzing several online tools. Oncomine database revealed that *TRIM13* was lower-expressed in invasive ductal and invasive lobular breast carcinoma, invasive lobular breast carcinoma, invasive ductal breast carcinoma, tubular breast carcinoma, mucinous carcinoma, ductal breast carcinoma *in situ*, breast carcinoma, invasive breast carcinoma, and medullary carcinoma with respect to normal tissues. For HER-2 criterion, there was no significant difference between positive and negative group. ER and PR status were positively correlated with *TRIM13* level. Conversely, SBR grade, NPI index, nodal status, basal-like status, and triple-negative status were negatively related to *TRIM13* expression in breast cancer patients in respect to normal individuals. Generally, breast cancer patients with ER or PR positive, nodal negative, non-basal-like or non-triple-negative status have a preferable outcome. Therefore, these results indicated that high expression of *TRIM13* may predict a better prognosis.

We further investigated the prognostic value of *TRIM13* in breast cancer using the PrognoScan and bc-GenExMiner software. The pooled results showed that lower *TRIM13* expression correlated with worse distant metastasis free survival, relapse free survival, disease specific survival, and metastatic relapse free survival. Such findings are in agreement with the notion of *TRIM13* as a tumor suppressor gene and a useful predictive biomarker for prognosis of breast cancer. We finally checked the co-expression of *TRIM13* gene using the Oncomine, bc-GenExMiner, and UCSC Xena web-based tools and found that *RAB11FIP2* was positively correlated with *TRIM13* expression. *RAB11FIP2*, a member of the RAB11 family of interacting proteins, exhibited potential tumor suppressor function since blocking of the *miR-192/215-RAB11FIP2* axis could inhibit gastric cancer progression \[[@B28]\]. This observation, along with our findings of *TRIM13* in survival information, provides evidence that *TRIM13* gene might inhibit tumor migration and invasion associated with *RAB11FIP2* expression.

In conclusion, the present work suggests that *TRIM13* was lower-expressed in different subtypes of breast cancer compared with normal tissues and was associated with several clinical parameters. *TRIM13* could be adopted as a promising predictive biomarker for prognosis of breast cancer with co-expressed *RAB11FIP2* gene. More in-depth experiments and clinical trials are needed to validate the value of *TRIM13* in breast cancer treatment.
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